Relationship between expression of β-tubulin-III plus stathmin in advanced non-small cell lung cancer and its sensitivity to venorelbine chemotherapy

Chinese Journal of Lung Cancer

Volumn 12, Issue 1, 2009, Pages 49-53

  Pu, Xiaolin ^a   Wang, Jun ^a   Xu, Lin ^b   Ma, Junqing ^c   Wang, Zhilu ^c   Liu, Fuyin ^a   Yang, Min ^a   Fan, Weifei ^a   Meng, Lijuan ^a  

^a BEIJING HOSPITAL   (China)

^b JIANGSU CANCER HOSPITAL   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

tubulin III; Chemotherapy; Lung neoplasms; Stathmin

Indexed keywords

BETA ACTIN; BETA TUBULIN; BETA TUBULIN 3; CARBOPLATIN; CISPLATIN; NAVELBINE; STATHMIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR BIOPSY; WESTERN BLOTTING;

EID: 60149102576     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2009.01.008     Document Type: Article

References (16)

1. Sarries C, Haura EB, Roig B, et al. Pharmacogenomic strategies for developing customized chemotherapy in non-small-cell lung cancer. Pharmacogenomics, 2003, 3(6): 763-780.
2. Xia Y, Hu CP, Zhang MC, et al. Relationship between ERCC1 expression and cisplatin intervention in human lung adenocarcinoma cell lines. Chin J Lung Cancer, 2007, 10(5): 362-365.
3. Yu ZY, Ouyang XN, Du J, et al. Express of insulin-like growth factor-receptor in non-small-cell lung carcinoma patients and its clinical significance. Chin Oncol, 2006, 16(8): 638-640.
4. Liao RQ, Lin JY, Qiao GB, et al. RRM1 expression in tissue microarray and prognosis analysis in non-small cell lung cancer. Chin J Lung Cancer, 2006, 9(5): 423-427.
5. Jing XR, Liu L, Zhao H, et al. Relationship between expression of Stathmin gene in cancer cells and its sensitivity to chemotherapeutic drugs. Fourth Milit Medi Univ, 2005, 26(9): 784-788.
6. Alli E, Bash Babula J, Yang JM, et al. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res, 2002, 62(23): 6864-6869.
7. Bhattacharya R, Cabral F. A ubiquitous beta-tubulin disrupts microtubule assembly and inhibits cell proliferation. Mol Biol Cell, 2004, 15(7): 3123-3131.
8. Mori N, Morii H. SCG10-related neuronal growth-associated proteins in neural development, plasticity, degeneration, and aging. J Neurosci Res, 2002, 70(3): 264-273.
9. Chen W, Ji J, Xu X, et al. Proteomic comparison between human young and old brain by two-dimensional gel electrophoresis and identification of proteins. Int J Dev Neurosci, 2003, 21(4): 209-216.
10. Campostrini N, Marimpietri D, Totolo A, et al. Proteomic analysis of anti-angiogenic effects by a combined treatment with vinblastine and rapamycin in an endothelial cell line. Proteomics, 2006, 6(15): 4420-4431.
11. Rubin CI, Atweh GF. The role of stathmin in the regulation of the cell cycle. J Cell Biochem, 2004, 93(2): 242-250.
12. Gigant B, Wang C, Ravelli RB, et al. Structural basis for the regulation of tubulin by vinblastine. Nature, 2005, 435(7041): 519-522.
13. Seve P, Lai R, Ding K, et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res, 2007, 13(3): 994-999.
14. Seve P, Isaac S, Tredan O, et al. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res, 2005, 11(15): 5481-5486.
15. Gan PP, Pasquier E, Kavallaris M. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res, 2007, 67(19): 9356-9363.
16. Rosell R, Scagliotti G, Danenberg KD, et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene, 2003, 22(23): 3548-3553.